ImmuCell Corporation (ICCC)

Currency in USD
9.540
-0.140(-1.45%)
Real-time Data·
ICCC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
9.5309.650
52 wk Range
4.52010.750
Key Statistics
Prev. Close
9.68
Open
9.59
Day's Range
9.53-9.65
52 wk Range
4.52-10.75
Volume
5.1K
Average Volume (3m)
25.68K
1-Year Change
46.9954%
Book Value / Share
3.22
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ICCC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Operates with a moderate level of debt

ImmuCell Corporation News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

ImmuCell Corporation Earnings Call Summary for Q1/2026

  • ImmuCell achieved first $10M+ revenue quarter with Q1 2026 sales of $10.36M, up 28.4% YoY; EPS rose 31% to $0.21 from $0.16 prior year
  • Domestic sales surged 35.7% while international sales declined 30.2%; gross margin expanded to 45% from 41.6% on operational efficiencies
  • Stock climbed 3.64% to $8.55 in premarket trading following results, approaching 52-week high of $9.08
  • Company plans manufacturing capacity expansion for First Defense product line; operating expenses increased 22.7% to $2.7M YoY
  • Management focuses on calf scours prevention market growth despite risks from rising costs and international sales weakness
Last Updated: 2026-05-15, 10:08 a/m
Read Full Transcript

Earnings

Latest Release
May 14, 2026
EPS / Forecast
0.21 / --
Revenue / Forecast
10.36M / --
EPS Revisions
Last 90 days

ICCC Income Statement

Compare ICCC to Peers and Sector

Metrics to compare
ICCC
Peers
Sector
Relationship
P/E Ratio
−158.2x−2.9x−0.5x
PEG Ratio
1.41−0.060.00
Price/Book
3.0x2.4x2.6x
Price / LTM Sales
2.9x103.5x3.0x
Upside (Analyst Target)
-142.0%58.6%
Fair Value Upside
Unlock−6.7%10.2%Unlock

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is based in Portland, Maine.

Employees
73

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
457.02K5.05%4.42M
Other Institutional Investors
2.65M29.31%25.67M
Public Companies & Retail Investors
5.94M65.64%57.48M
Total
9.05M100.00%87.57M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
SRK Fund I, LP5.55%502,2584,862
SRK Capital, LLC5.55%502,2584,862

People Also Watch

12.07
SVCO
-0.82%
26.920
PPIH
+6.15%
131.86
NWPX
+2.34%
25.010
CUE
+1.96%
103.34
MLAB
-2.03%

FAQ

What Is the ImmuCell (ICCC) Stock Price Today?

The ImmuCell stock price today is 9.540 USD.

What Stock Exchange Does ImmuCell Trade On?

ImmuCell is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for ImmuCell?

The stock symbol for ImmuCell is "ICCC."

What Is the ImmuCell Market Cap?

As of today, ImmuCell market cap is 86.310M USD.

What Is ImmuCell's Earnings Per Share (TTM)?

The ImmuCell EPS (TTM) is -0.069.

When Is the Next ImmuCell Earnings Date?

ImmuCell will release its next earnings report on Aug 19, 2026.

From a Technical Analysis Perspective, Is ICCC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

How Many Times Has ImmuCell Stock Split?

ImmuCell has split 1 times.

How Many Employees Does ImmuCell Have?

ImmuCell has 73 employees.

What is the current trading status of ImmuCell (ICCC)?

As of Jun 15, 2026, ImmuCell (ICCC) is trading at a price of 9.540 USD, with a previous close of 9.680 USD. The stock has fluctuated within a day range of 9.530 USD to 9.650 USD, while its 52-week range spans from 4.520 USD to 10.750 USD.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.